drugset / Trial / NCT03555032

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

NCT03555032

Phase 1/2 Completed 15 enrolled Royal Marsden NHS Foundation Trust
NaSingle-groupOpen-labelTreatment

Summary

This study will look at the safety and effects of combining a new drug called Talimogene Laherparepvec (T-VEC) with chemotherapy delivered by Isolated Limb Perfusion (ILP). The investigators want to find out whether these two treatments can be combined safely and whether T-VEC with ILP is better at treating your cancer than with ILP alone.

Timeline

Start
2018-06-26
Primary completion
2021-08-01
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 1e+06 unknown Other
Subject Talimogene Laherparepvec Other / unclassified 1e+08 unknown Other

Indications